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Abstract
This chapter aims to highlight the main types of infections in the ICU, in order to improve 
diagnostic and therapeutic management. Risk factors for patients hospitalised in the 
ICU will be raised: the increasing use of invasive devices and procedures, aggressive 
antimicrobial therapies, surgical interventions, immunosuppressive treatments or co-
morbidities responsible for immune deficiencies. Starting from the rising mortality risk 
among patients with hospital-acquired infections (HAI), in the case of failure to control 
the pathogen in the first 24–48 h, we will tackle about the prevention, reduction and 
control of the emergence of resistant pathogens. The rational administration of antibiotics 
will also be addressed, with the aim of reducing adverse reactions, including secondary 
infections, decreasing the mortality rate, length of hospital stay and costs of health care.
Keywords: ventilator-associated pneumonia, intra-vascular catheter-related 
bacteraemia, sever sepsis, septic shock, antimicrobial treatment, multidrug resistance
1. Introduction
Modern medicine is a tributary to a continuously increasing degree of diagnostic and thera-
peutic invasiveness. In particular, intensive care units (ICUs) are confronted with increasing 
number of patients with marked co-morbidities, severe acute pathology or immune suppres-
sion, and intrinsic infectious risk factors. Additionally, given the pathogenicity changes of 
potentially hospital-acquired pathogens, most healthcare-associated infections (HCAIs) are 
caused by multidrug-resistant organisms (MDRO).
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. ICU infections
2.1. Severe respiratory infections
Pneumonia is one of the infections frequently requiring hospital admission and urgent anti-
microbial treatment due to the risk of rapid evolution to respiratory and multiple organ fail-
ure, especially in immunocompromised patients, or when caused by MDRO. The diagnosis of 
severe pneumonia requires ICU admission given the need for assisted ventilation or oxygen 
therapy, in the presence of radiological changes, confirming the rapid progression, as well as 
the evolution towards sepsis [1, 2].
Community-acquired pneumonia (CAP) is caused by bacteria in 85% of cases, the most 
frequently involved pathogens being Streptococcus pneumoniae, Haemophilus influenzae and 
Moraxella catarrhalis. Severe CAP cases may also be produced by other pathogens (influenza 
viruses, coronaviruses, Hanta virus, Legionella).
Pneumonia may trigger acute myocardial infarction in patients with heart diseases, while in 
splenectomised patients or with spleen dysfunction, S. pneumoniae may cause severe sepsis 
with lethal outcome within 12–24 h from onset, even under antibiotic therapy.
The treatment of CAP must cover both typical and atypical pathogens. Clinical studies have 
shown that monotherapy with respiratory fluoroquinolones or tigecycline is almost as effec-
tive as therapy with antibiotic associations (ceftriaxone plus doxycycline, azithromycin, or 
respiratory quinolones) [3].
On the other hand, presently ICUs are especially confronted with respiratory infections 
acquired during hospitalisation. According to 2012/506/EU European Parliament Decision, 
hospital-acquired pneumonia (HAP) occurs 48 h or more after admission and was not incu-
bating at the time of admission, while ventilated-associated pneumonia (VAP) arises in 48 h 
after endotracheal intubation [4]. The microorganisms involved in the aetiology of these 
pneumonia cases originate in the oropharyngeal or upper airways colonisation flora or by 
direct inoculation of contaminated solutions, via an endotracheal catheter, or exogenous con-
tamination of respiratory equipment caused by health care staff.
The hospital-acquired risk factors associated with this type of infection are:
• long time sedation,
• general anaesthesia with endotracheal intubation,
• other invasive procedures: bronchoscopy, nasogastric catheterisation,
• prolonged use of assisted ventilation,
• reintubation, change of ventilation circuits at intervals under 48 h,
• post-trauma intubation,
• tracheostomy,
• corticotherapy or other immunosuppressive treatments,
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• antibiotic therapy, administration of antacids or H2 blockers, barbituric therapy after cra-
nial traumas,
• thoracic or upper abdominal surgery,
• emergency surgery,
• administration of over 4 units of blood before the surgical intervention [5, 6].
These factors disturb respiratory functions leading to obstructions, decreased pulmonary vol-
ume, decreased filtration of inhaled air, and decreased secretion clearance. The insertion of an 
endotracheal tube allows the direct access of pathogens into the lower airways or may cause 
lesions of the epithelial mucosa, which represent breaches. Additionally, inadequate hand 
hygiene of medical personnel, lack of adherence to universal precautions, errors in decon-
tamination of equipment or in the practice of endotracheal aspiration may favour not only 
cross-contamination but also the direct access of a massive bacterial inoculum.
This pneumonia is caused by a wide range of pathogens, and it may be plurietiological 
and is only rarely caused by viruses or fungi. The aetiological agents frequently involved 
in such infections are not only Gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella spp., 
Escherichia coli) but also Gram-positive cocci such as Staphylococcus aureus. The frequency 
of MDRO is increasing and influences the treatment, as in the case of methicillin-resistant 
Staphylococcus aureus (MRSA), carbapenem-resistant Pseudomonas, fluoroquinolones, antip-
seudomonal penicillins and cephalosporins, extended-spectrum beta-lactamase-producing 
Enterobacteriaceae (ESBL), Acinetobacter baumannii, etc. The risk factors for MDRO infections 
are the use of antibiotics during the previous 90 days, the onset of pneumonia after 4 days of 
hospitalisation, circulation of such pathogens in the health care unit in question, as well as the 
presence of comorbidities (immune suppression or immunosuppressive treatments).
The diagnosis of HAP should be rapidly reached, and the antibiotic treatment has to be prom-
ptly introduced, and any delay potentially aggravates the evolution and prognosis. The first 
antibiotic of choice depends on infection severity, patient’s risk factors, and the number of 
hospitalisation days accumulated until the onset of pneumonia.
The empirical treatment of HAP or VAP occurring during the first five hospitalisation days in 
patients without risk factors for MDRO must include antibiotics active against not only aero-
bic Gram-negative bacilli (Enterobacter spp., E. coli, Klebsiella spp., Proteus spp., Serratia spp.), 
pathogens with respiratory tropism (Haemophilus influenzae and Streptococcus pneumoniae), but 
also methicillin-sensitive S. aureus (MSSA). Recommendations include therapeutic schemes 
based on ceftriaxone or a fluoroquinolone (ciprofloxacin or levofloxacin) or ampicillin-sulbac-
tam or ertapenem (Figure 1).
In the case of patients with HAP or VAP who are at risk for MDRO infection, regardless 
of the infection’s severity, the antibiotic treatment must be directed against P. aeruginosa, K. 
pneumoniae (ESBL-producing strains), Acinetobacter spp. and MRSA. Antibiotic associations 
including antipseudomonal cephalosporins (ceftazidime), an antipseudomonal carbape-
nem (imipenem) or beta-lactam/beta-lactamase inhibitors (piperacillin-tazobactam), will be 
administered, in association with antipseudomonal fluoroquinolones (ciprofloxacin) or an 
Infections and Multidrug-Resistant Pathogens in ICU Patients
http://dx.doi.org/10.5772/intechopen.79229
17
aminoglycoside (tobramycin) and vancomycin or linezolid, to cover MRSA. If a Legionella 
infection is suspected, a macrolide (azithromycin) must also be associated [7] (Table 1).
The duration of the antibiotic treatment in HAP must be adjusted to the severity of the dis-
ease, the time required to obtain clinical improvement and the aetiological agent, but it has to 
exceed with at least 3 days the time to clinical improvement. The clinical response occurs after 
Table 1. Empirical antibiotic treatment of HAP with MDRO.
Figure 1. Antibiotic therapy in HAP.
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at least 48–72 h, a period during which the recommendation is to maintain the therapeutic 
scheme. If, after this interval of empirical treatment, the clinical status of the patient did not 
improve, the therapeutic scheme must be broadened, potential complications (pleurisy, pul-
monary abscess) and/or non-infectious causes must be sought.
2.2. Bacteraemia and septicaemia
2.2.1. Generalised septicaemic infections
The generalised septicaemic infection is an infection with an unpredictable outcome, high 
severity and increased mortality in the absence of adequate treatment. The correct choice of 
empirical antibiotic treatment depends on the intelligent use of clinical knowledge and epi-
demiological and microbiological data regarding the pathology in the area where the patient 
comes from. The lack of knowledge on the local resistance prevalence is a predictive factor for 
an incorrect treatment. The basic principle, which guides the treatment of the critical patient, 
is to rapidly initiate antibiotic treatment at correct doses, concordant with the pharmacoki-
netic and pharmacodynamic characters of the chosen drug and to adapt the treatment to the 
changes occurring in the clinical evolution and to the results of the antimicrobial sensitivity 
tests as soon as these become available.
Immediately after a patient with suspected sepsis is admitted, an attentive anamnesis and a 
thorough clinical examination are conducted in order to establish the entry and the location 
of the primary and secondary septic sites. The first emergency microbiological investigations 
are conducted (repeated blood cultures, cultures from secretions, lesions, urine, sputum, exu-
dates, pleural fluid, etc.) together with evaluations of the renal, hepatic functions and state of 
consciousness, thus determining the severity of the case [8, 9].
The practical approach includes the emergency admission of the patient into the ICU 
where prevention or correction of hypovolemia, functional and metabolic dysfunctions are 
attempted, concomitantly with the prompt initiation of antibiotic treatment according to the 
maximal probability criterion.
The correct antibiotic treatment targets the resident microbial flora in the organ presumed to 
be the source of the infectious process.
The empirical treatment of sepsis consists of the association of bactericidal antibiotics with syn-
ergistic actions or monotherapy with an ultra-broad-spectrum antibiotic; antibiotics are admin-
istered intravenously in order to rapidly achieve an effective concentration in the infection site.
Empirical antibiotic therapy proved to be equally effective in beta-lactam-aminoglycoside 
associations, monotherapy with carbapenems, broad-spectrum penicillins/beta-lactamase 
inhibitors (ticarcillin/clavulanic acid, piperacillin/tazobactam) or third- and fourth-generation 
cephalosporins [10].
The aetiology of sepsis varies with the age of the patient, and the empirical treatment must 
be adapted to the most probable aetiology, but correlated with age, weight and associated 
pathology.
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Adults with severe sepsis of unknown source must be treated with antibiotics effective 
against Gram-negative bacilli, Staphylococcus aureus, streptococci, respectively carbapenems 
(meropenem or imipenem) plus vancomycin. Septic shock requires the urgent refilling of 
the vascular system by infusions with saline solutions until the central venous pressure is 
re-established (over 80 mm at 6 h from hospital admission); at the same time, the primary 
source of infection is investigated, blood culture is collected and the first dose of antibiotic is 
administered, knowing that the time from admission to the initiation of antibiotic therapy is 
the strongest prognostic factor.
Patients admitted in a state of septic or toxic-septic shock will not be treated with beta-
lactam (The bacterial load is very high, the pathogens are in a stationary phase with low 
protein synthesis, hence with a low synthesis of penicillin-binding proteins, so antibiotics 
lack their target.)
Colistin has a rapid antibacterial effect completed by a significant post-antibiotic effect against 
P. aeruginosa, A. baumannii and K. pneumoniae. The most effective administration regimen is at 
8 h. Colistin proved an important alternative in the treatment of MDR Gram-negative bacilli. 
Resistance to colistin is caused by sub-optimal doses. Colistin dosage must be optimised, as 
this antibiotic is the last option in the treatment of MDRO [11–13].
When a biliary infection is suspected to be at the origin of bacteraemia, the most frequently 
encountered bacteria are enterococci and aerobic Gram-negative bacilli, which respond well 
to piperacillin/tazobactam or ticarcillin/clavulanate; alternatively, ceftriaxone, ciprofloxacin 
or levofloxacin associated to metronidazole may be administered.
A great part (around 25%) of sepsis cases occur as a result of community or hospital-acquired 
urinary tract infections (UTI), evolving with a renal or complication of prostatic parenchyma. 
In such cases, the time from hospital admission to the initiation of antibiotic treatment is 
also decisive for the evolution. After collection of samples for blood and urine cultures, the 
first dose of broad-spectrum antibiotic active against E.coli, Proteus spp., Enterobacter spp., 
Klebsiella spp., P. aeruginosa is administered; more rare cases of sepsis of urinary origin may 
be caused by Gram-positive bacteria (15%) or by Pseudomonas spp., especially in patients with 
immune deficits. For an effective treatment of community-acquired urosepsis, depending on 
the type of local susceptibility, a third-generation cephalosporin or a fluoroquinolone may 
be indicated; in urosepsis following urologic surgery in patients with long-term urinary 
catheters, the association of a third-generation cephalosporin active against Pseudomonas or 
piperacillin/tazobactam with an aminoglycoside or a carbapenem is useful, this association 
being required to cover MDRO [14].
It should be noted that treatment in sepsis is complex, antibiotic therapy being accompanied 
with measures to eradicate the entry site and septic metastases, to correct tissue hypoxia and 
to maintain hydro-electrolyte and acid-base balance.
2.2.2. Infections associated with invasive devices
Invasive devices (endotracheal, intra-vascular catheters) increase the risk of HCAI especially 
with MDRO, by colonisation and biofilm formation on the internal surface of these devices. 
All types of intra-vascular devices may become complicated with blood infections, but arterial 
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catheters used for the haemodynamic monitoring and peripheral catheters show lower infec-
tion risks than central venous caterers (Table 2).
The removal of intra-vascular, gastric or bladder catheters, neurosurgical shunts, etc. as soon 
as they are no longer needed, represents an infection prevention measure. Both their insertion 
and removal is done by specialised staff, trained to work under sterile conditions, avoiding 
the risk of contamination. Knowing that invasive devices, catheters included, are the most fre-
quent cause of HCAIs, their insertion must be conducted under aseptic conditions, choosing 
the most suitable site (for instance, sub-clavian rather than femoral), after ensuring the asepsis 
of the cutaneous area, preferably with chlorhexidine, and not with alcohol or iodine solutions. 
In severely immunocompromised patients, the recommendation is to use antibiotic-impreg-
nated catheters. Clinical studies confirm the significant reduction in catheter-associated infec-
tions when these are removed as soon as their role is no longer essential [15–17].
An increasing number of patients require central venous catheters for long periods of time 
(for haemodialysis, total parenteral nutrition, chemotherapy), which favours complications 
such as thrombosis or infection. Central venous catheter-associated bacteraemia imposes the 
removal of the catheter and systemic administration of antibiotics. The clinical decision to 
remove a catheter suspected of infection relies on the presence of local infection signs. The 
decision to maintain the device is made in the absence of severity signs in patients with tech-
nical difficulties of catheter reinsertion in a new site.
There are situations when catheters may not be removed or replaced (lack of venous approach, 
counter indication of a new intervention, etc.). In such cases, attempts are made to save the 
venous line by eliminating the intra-luminal colonisation before the onset of bacteraemia 
or, once bacteraemia is present, the general administration of antibiotic is associated with 
exposing the inner surface of the catheter, after its closure, at a very high concentration of the 
adequate antibiotic meant to eradicate the colonisation. This technique proved effective in 
the case of Gram-negative bacilli and coagulase-negative staphylococci, but it is not recom-
mended in colonisations with S. aureus [18].
2.3. Urinary tract infections
UTIs are the most frequent HCAIs. In most hospitals, catheter-related bacteriuria represents 
40% of all HCAI within 1 year. The decision to treat is made after discriminating between 
the presence of bacteria (colonisation) and symptomatic infectious processes. The signs of 
Table 2. Distribution of the infection risk in the intra-vascular catheterisation.
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catheter-associated UTIs are fever, lateral lumbar pain, sensitivity in the costovertebral angle, 
haematuria and delirium with recent onset. After catheter removal, pollakiuria or dysuria 
may be present.
The Infectious Disease Society of America defines asymptomatic bacteriuria as the absence of 
symptoms with the presence of over 105 colony forming units/ml of one or more bacterial spe-
cies in a catheterised patient. In most cases of asymptomatic bacteriuria, the treatment led to 
the temporary sterilisation of urine and not to the eradication of pathogens [19]. Additionally, 
in 33–50% of patients, after catheter removal, the bacteriuria spontaneously resolved. This is 
why treating an asymptomatic bacteriuria increases the risk of antimicrobial resistance or of 
adverse reactions associated with useless antibiotic treatment.
Some pathogenic bacteria produce biofilms, which consist of an adherent layer of microorgan-
isms and their extracellular products. The biofilm protects the pathogens against the host’s 
defence mechanisms and against antibiotic therapy. Migration to the urinary bladder occurs 
in 1–3 days. The duration of catheterization is an important risk factor, with almost all patients 
who are catheterised for more than 30 days developing bacteriuria. These patients are at risk of 
upper urinary tract inflammation, which increases the risk of bacteraemia. Infections linked to 
long-term catheterisation are often polymicrobial, which involves a broad-spectrum treatment.
The selection of antibiotics used for the treatment of catheter-associated UTIs depends on the 
result of the microscopical examination, as well as on the colonial characters. In 60–80% of 
cases, the causative agent is a Gram-negative bacillus (E.coli, Klebsiella spp., Pseudomonas spp., 
Proteus spp., Enterobacter spp.). The remaining 20–40% is caused by Gram-positive bacteria, 
most often species of staphylococci or enterococci. The empirical treatment has to take the fol-
lowing factors, which increase the risk of antibiotic resistance: the duration of hospitalisation, 
previous administration of antibiotics, and local resistance patterns.
Urinary fluoroquinolones (ciprofloxacin and levofloxacin) are administered to patients with 
mild and moderate infections, who are considered haemodynamically stable and do not 
present an altered mental status. Moxifloxacin is not recommended, as it does not reach effec-
tive urine concentrations. Broad-spectrum cephalosporins, ceftriaxone or cefepime, may also 
be used. In patients with urosepsis or in those haemodynamically unstable (hypothermia, 
tachycardia over 90/minute, tachypnoea over 20 respirations/minute or Pco2 under 33 mmHg, leukocytosis over 12,000/mm3 or leukopenia under 4000/mm3) piperacillin-tazobactam is 
administered.
In medium clinical forms, ciprofloxacin, 400 mg iv, for every 12 h or levofloxacin 500 mg iv /24 h 
or ceftriaxone for 1 g iv/day are administered.
The recommended treatments in severe forms include: cefepime 2 g iv/12 h, ceftazidime 2 g iv/8 h, 
imipenem 500 mg iv/6 h, doripenem 500 mg iv/8 h, meropenem 1 g/8 h and piperacillin/tazo-
bactam 3.375 g iv/6 h.
The treatment of UTIs associated with bladder catheterisation is done with antibiotics for 
3 days in women aged over 65 years, from whom the catheter has been removed; otherwise, 
the treatment is given for 7 days. The duration of levofloxacin treatment is 5 days.
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Most hospital-acquired UTIS are expensive and may be prevented. The implementation of 
protocols based on present guidelines will reduce the inadequate use, as well as the antimi-
crobial resistance. When catheterisation is necessary, its duration should be limited. In case 
infections occur, the empirical treatment should be conducted according to the suspected 
pathogens and on the hospital’s antibiogram. When the results of cultures become available, 
antibiotics narrow their spectrum. The treatment should be limited to 7–14 days, depend-
ing on the response to treatment. Catheter removal is a key factor because catheterisation 
increases the risk for hospital-acquired UTI and other complications, resulting in prolonged 
hospitalisation and increased costs [20, 21].
2.4. Intra-abdominal infections
Intra-abdominal infections include a series of diseases with variable severity, from uncom-
plicated appendicitis to faecal peritonitis. Uncomplicated infections involve a single organ 
and may not reach the peritoneum, and they may be solved either by surgical resection or by 
administration of antibiotics. Complicated intra-abdominal infections are those which extend 
to the peritoneum causing localised or generalised peritonitis; in order to solve these, the 
infection source must be solved by both surgery and antibiotic therapy.
The antimicrobial therapy of intra-abdominal infections, which are to be solved percutane-
ously or by surgery, has the following goals: to accelerate the elimination of the infecting 
microorganisms, to decrease the recurrence risk of the intra-abdominal infection, to shorten 
the clinical evolution, to limit the expansion of the infection to the abdominal wall and to 
decrease the risk of generalisation of the infectious process.
The antibiotic therapy is initiated after hydroelectrolyte rebalance, the restored volemia deter-
mining the restoration of the visceral perfusion and a better distribution of the medication. 
Moreover, this diminishes the side effects of antibiotics, which have been exacerbated by the 
deficitary perfusion of internal organs.
The empirical antibiotic treatment is initiated in concordance with the most probable micro-
biological spectrum, the type and density of germs being dependant on the level where the 
perforation of the digestive tract has occurred. By gastric, duodenal and proximal jejunal 
perforations, a low number of aerobic Gram-positive and anaerobic Gram-negative bacteria, 
generally sensitive to cephalosporins, are released into the peritoneum. Candida albicans has 
also been isolated, but antifungal treatment is only required in the case of patients under 
immunosuppressive treatment or in patients with recurrent intra-abdominal infections. The 
perforations of the distal small intestine often evolve as localised abscesses and peritonitis 
only takes place when these are ruptured. The intra-abdominal infections propagated from 
the colon into the peritoneum are caused by anaerobic or facultative anaerobic Gram-negative 
bacteria; Bacteroides fragilis is sometimes present.
The selection of the antibiotic should then be guided by the results of the cultures from the 
biological specimens obtained by percutaneous drainage or during the surgical interven-
tion, but until these become available, it is necessary and useful to perform the microscopical 
examination directly on a Gram-stained smear. If high numbers of Gram-positive cocci are 
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present, these are very likely to be enterococci or other faecal streptococci, which imposes the 
association of vancomycin.
Aerobic and anaerobic Gram-negative cocci may be covered by administration of cefoxitin, 
ampicillin/sulbactam, piperacillin/tazobactam, imipenem, meropenem, moxifloxacin, while 
aerobic Gram-negative bacilli may be destroyed with aminoglycosides, second-, third- and 
fourth-generation cephalosporins, aztreonam, antipseudomonal penicillins or fluoroqui-
nolones (ciprofloxacin, levofloxacin). It must be mentioned that ertapenem is not active on 
Pseudomonas aeruginosa and Acinetobacter spp., and in the case of critical patients infected with 
P. aeruginosa, the dose of meropenem must be increased to 1 g administered for every 6 h. 
Vancomycin-resistant enterococci produce extremely difficult to treat infections, the only 
useful antibiotic being daptomycin. Tigecycline has been approved for the treatment of com-
plicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, E. coli, 
Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible), MSSA, 
MRSA and some anaerobic bacteria [22].
The antibiotic, which is active only against Gram-negative bacilli and anaerobic bacteria, is 
metronidazole, for which no resistance has been reported.
The patients at high risk of unfavourable evolution and reserved prognosis have a high 
APACHE II score, poor nutritional status, significant cardiovascular diseases, immune sup-
pression induced by medicines or by co-morbidities, while the infection source cannot be 
controlled. The predictive factors of therapeutic failure include the duration of the evolution 
prior to hospital admission, more than 2 days of presurgical treatment, as well as the presence 
of the MDRO. These patients should be treated similarly to those with hospital-acquired infec-
tions with carbapenems and vancomycin, but also considering the local antibiotic resistance.
The antibiotic treatment must be administered until the resolution of the clinical signs of 
infection (normalisation of the thermal curve, restoration of the intestinal transit) and nor-
malisation of the biological inflammatory syndrome.
In cases with recurrent intra-abdominal infections, the diagnosis must be reassessed after 
5–7 days of treatment and the investigations should be broadened (echography, CT). Often, 
the antibiotic therapy must be adjusted or a new surgical intervention is required in order to 
eliminate the site of infection.
2.5. Meningitis
The antibiotic treatment must be urgently initiated, immediately after blood collection for 
blood culture and after performing the lumbar puncture. Delayed administration of the first 
dose of antibiotic is associated with an aggravated prognosis, and it is a strong independent 
factor of increased mortality, exceeding the importance of disease severity upon hospital 
admission and of the isolation of a penicillin-resistant strain.
The most frequent cause of delayed antibiotic therapy is the missed diagnosis due to an 
atypical form of meningitis (absence of fever, headache or neck stiffness). Another possible 
cause of temporization is represented by scheduling the imagistic investigation immediately 
after admitting the patient in whom the spinal tap is not safe: risk of a cerebral hernia after 
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cerebrospinal fluid (CSF) collection, in cases of expansive intra-cranial processes accompa-
nied by papilledema or focal signs. In this latter situation, computerised tomography (CT) or 
nuclear magnetic resonance (NMR) examinations should be conducted after blood collection 
for blood culture and after the first dose of antibiotic, despite the risk of excessive treatment.
The antibiotic administration route in meningitis is intravenous, which is capable to ensure the 
CSF bactericidal concentrations; the exception is for rifampicin, which may be administered 
orally and is useful in the treatment of meningitis caused by beta-lactam-resistant pneumo-
coccus and coagulase-negative staphylococci.
Antibiotic selection: in the treatment of bacterial meningitis, bactericidal antibiotics able to cross 
the blood-brain barrier are administered, so that optimal CSF concentrations are ensured 
regardless of the meningeal inflammation degree (meningeal inflammation favours the pen-
etration of the antibiotic in the sub-arachnoid space at the onset of the disease, but as the 
inflammation regresses under treatment, the concentration tends to decrease, so that higher 
doses are required as compared to other diseases) [23].
Patients with suspected bacterial meningitis will be initially treated with a broad-spectrum 
antibiotic concordant to the most probable aetiology, the selection being made depending 
on the age and comorbidities. After establishing the aetiology and antibiotic susceptibility of 
the isolated pathogen, the antibiotic therapy will be focused, maintaining the high doses and 
intravenous administration.
The lumbar puncture should be repeated after the first 24–36 h from the initiation of the treat-
ment in order to assess CSF cytological, biochemical and bacteriological changes.
The immune competent adult with bacterial meningitis requires an initial antibiotic treatment 
aiming at meningococcus and pneumococcus, consisting in the association of ceftriaxone 
(2 g/12 h) or cefotaxime (2 g/6 h) with vancomycin (30–60 mg/kg/day for every 8 or 12 h); 
third-generation cephalosporins must be administered even if the antibiogram shows that 
the respective strain presents intermediate sensitivity or resistance, because vancomycin acts 
synergically and increases the efficiency of the therapy [24].
Patients with bacterial meningitis and compromised cell immunity due to pre-existing condi-
tions or immunosuppressive treatment, but with conserved renal function, should be treated 
with vancomycin (60 mg/kg/day divided into two or three doses) plus cefepime (6 g/day 
divided into three doses) or meropenem (6 g/day divided into three doses).
If a Listeria infection is suspected, the empirical treatment may consist in the association 
between vancomycin and moxifloxacin (400 mg in a single daily dose) plus trimethoprim-
sulfamethoxazole (10–20 mg/kg/day divided at 6 or 12 h).
The duration of the antibiotic treatment in meningitis is not standardised, but it should be 
individualised based upon the clinical response of each patient, but usually 7 days of treat-
ment is sufficient for meningococcal and H. influenzae meningitis, 10–14 days for pneumococ-
cal meningitis, 14–21 days for meningitis with S. agalactiae and 21 days or more for meningitis 
with L. monocytogenes; meningitis with aerobic Gram-negative bacilli requires antibiotic 
administration for 21 or 14 days after the last CSF sterile culture.
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Hospital-acquired bacterial meningitis (HABM) may be the result of an invasive procedure 
(craniotomy, insertion of internal or external ventricular catheter, lumbar puncture, intrathe-
cal medication, spinal anaesthesia), of a complicated cranial trauma or, in more rare cases, of 
an infectious metastasis in patients with hospital-acquired bacteraemia. Such meningitis is 
caused by microorganisms with different spectra from community-acquired cases, and the 
disease is the result of particular pathogenetic mechanisms.
Bacterial meningitis is a redoubtable complication of craniotomy, occurring in 0.8–1.5% of 
the patients who undergo this procedure. One-third of the post-craniotomy meningitis cases 
develop during the first week after the surgical intervention, another third during the second 
week and one-third after the second week from the intervention, sometimes even years after 
the surgical procedure. The risk of post-surgical meningitis may be minimised by the atten-
tive use of surgical techniques, especially those which decrease the possibility of liquid fistu-
lae. Other factors associated with meningitis after craniotomy include concomitant infection 
at the incision site and duration of procedure exceeding 4 h.
The incidence of meningitis associated with internal ventricular catheters (cerebrospinal 
shunt) used in the treatment of hydrocephaly varies between 4 and 17%. The most important 
causative factor is the colonisation of the catheter at the time of insertion so that most infec-
tions become manifest in less than 1 month from the procedure.
External ventricular catheters are used to monitor intra-cranial pressure or to temporarily devi-
ate the CSF if there is an obstruction in the system or as a treatment component in cases of infec-
tion of the internal catheter. The rate of external catheter-associated infection is around 8%.
The incidence of meningitis after moderate or severe cranial trauma is 1.4%. The open cranial 
trauma is encountered in 5% of cranial trauma and is complicated by meningitis in 2–11% of 
cases. Most patients in whom meningitis occurs as a complication of closed cranial trauma 
present a skull base fracture, which creates a communication between the sub-arachnoid 
space and the sinus cavities, posing an infection risk of up to 25%. The average time interval 
between the trauma and the onset of meningitis is 11 days. The CSF leak is the major risk 
factor, even though most post-traumatic leaks are not diagnosed. Most fistulae resolve spon-
taneously within 7 days, a surgical intervention is recommended if the breach persists. The 
cranial trauma is the most frequent cause of recurrent meningitis.
The diagnostic procedure relies on neuroimagistic investigations, CSF analysis (cell count, 
biochemical tests for glucose, proteins, Gram staining, cultures) and blood cultures. Neuroima-
gistics is indicated in most patients as it allows the ventricular size evaluation and brings informa-
tion on a possible poor functioning of the shunt or the presence of residual catheters after previous 
surgical interventions.
The most frequently encountered bacteria in these cases are Gram-negative bacilli (Klebsiella 
pneumoniae, Pseudomonas aeruginosa), S. aureus and coagulase-negative staphylococci.
The empirical antibiotic therapy in HABM depends on the pathogenesis of the infectious 
process. In patients with meningitis occurring after neurosurgical interventions, or in patients 
with long-term hospitalisation after open cranial trauma or skull base fractures, vancomy-
cin is associated with cefepime, ceftazidime or meropenem; the second antibiotic is selected 
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depending on the local chemotherapeutics susceptibility profiles of Gram-negative bacilli. 
The empirical treatment in skull base fracture or early after ENT surgery includes vanco-
mycin plus a third-generation cephalosporin (cefotaxime, ceftriaxone). After isolating the 
involved pathogen, antimicrobial therapy is changed for an optimal management. Linezolid 
and daptomycin are effective in staphylococcal meningitis; linezolid has good pharmacoki-
netic properties—CSF penetration is around 80%.
The initiation of empirical treatment is recommended in all patients with post-surgical signs 
of meningitis; this is withdrawn after 72 h in case the results of CSF cultures are negative. The 
treatment must be individualised, especially in patients previously treated with antibiotics, in 
whom the treatment is continued despite the negative results of cultures.
Given the emergence of MDR Gram-negative bacilli, the antimicrobial therapy of HABM 
caused by these pathogens becomes problematic. This is especially true in cases of HABM 
caused by Acinetobacter baumannii species, bacteria with acquired resistance to third- and 
fourth-generation cephalosporins and even to carbapenems. The treatment of Acinetobacter 
meningitis includes meropenem associated with an aminoglycoside administered intra-ven-
tricularly or intrathecally. If the identified isolate is resistant to carbapenems, intra-ventricular 
or intrathecal administration of colistin or polymyxin B will be given instead of meropenem.
Treatment protocols recommended depending on the pathogenesis of the infectious process:
• Infection after neurosurgical procedure—Gram-negative bacilli (including P. aeruginosa), 
Staphylococcus aureus and coagulase-negative staphylococci (S. epidermidis) may be involved. 
Vancomycin plus cefepime or meropenem are recommended.
• Ventricular or lumbar catheter—coagulase-negative staphylococci, S. aureus, Gram-negative 
bacilli (P. aeruginosa) and Propionibacterium acnes may be present. Vancomycin plus cefepime 
or meropenem are recommended.
• Penetrating trauma: S. aureus, coagulase-negative staphylococci, Gram-negative bacilli. 
Vancomycin plus cefepime or meropenem is administered.
• Skull base fracture: Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyo-
genes. Vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime) is 
recommended.
2.6. Infections of the skin and soft tissues
With the increasing incidence of MRSA, skin and soft tissue infections require more frequent 
admission of patients presenting tissue necrosis, fever, hypotension, intense pain, altered 
consciousness, respiratory, hepatic or renal failure, to the ICU. When choosing the therapeu-
tic scheme, the possibility of a polymicrobial infection must be considered, with consecutive 
need to cover not only MRSA but also Gram-negative and anaerobic bacteria. An inadequate 
initial empirical treatment is associated with prolonged evolution and hospital stay [25].
Perianal infections and abscesses, infected decubitus ulcers, and moderate and severe infec-
tions of the diabetic foot frequently involve multiple aetiologies and require coverage for 
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streptococci, MRSA, aerobic and anaerobic Gram-negative bacilli until the results of micro-
biological investigations become available.
In the case of patients with non-suppurative cellulitis, a beta-lactam antibiotic, such as cefazo-
lin, may be initially prescribed, which is to be replaced in case of unsatisfactory clinical evolu-
tion. The replacement will be made according to the result of the antimicrobial susceptibility 
test or with an antibiotic active on MRSA, if the pathogen has not been isolated in the culture. 
The empirical treatment of MRSA infections may include vancomycin, linezolid, daptomycin, 
tigecycline and telavancin. Linezolid, daptomycin, vancomycin and telavancin additionally 
also cover streptococcal infections and not only MRSA.
In case of a documented or suspected staphylococcal infection, the recommendation is to 
immediately initiate the antibiotic treatment according to maximal probability criteria and 
according to local data on the sensitivity of strains circulating in the respective area. The doses 
of antibiotic must be adequate, because sub-inhibitory concentrations favour the release of 
staphylococcal toxins and virulence factors (PVL—Panton-Valentine leukocidin), which trig-
ger the onset of skin, lung or bone necrotic lesions. Catheters and intra-vascular devices must 
be removed. In cases with detected abscesses, these should be drained; the localised infection 
of a prosthetic joint requires the removal of the prosthesis, but if the infection is located on a 
valvular prosthesis, its removal is not always required.
The treatment of MRSA infections frequently includes the administration of vancomycin. The 
increased vancomycin consumption has posed an increasing selection pressure of staphylo-
coccal strains resistant to this antibiotic. The concentration of vancomycin required to inhibit 
most S. aureus strains is 0.5–2 mg/l. The strains with a minimum inhibitory concentration 
(MIC) of vancomycin between 8 and 16 mg/l are classified as intermediate sensitive or VISA 
(vancomycin-intermediate S. aureus), while strains with MIC ≥32 mg/l are considered resis-
tant or vancomycin-resistant S. aureus (VRSA). The resistance mechanisms are different in 
the two types of strains: in VISA strains, the bacterial cell wall is thickened by the altered 
biosynthesis process and the glycopeptides targets are hidden in its thickness and in the case 
of VRSA strains, the target of glycopeptides is itself modified.
Surgical wound infections are another category of infections frequently confronting ICUs. 
In their most frequently polymicrobial aetiology, Gram-positive cocci (especially MRSA), 
Enterobacteriaceae and non-fermentative Gram-negative bacilli (P. aeruginosa) are among the 
most frequently isolated pathogens. The empirical treatment of these infections consists of 
associating cefepime or meropenem with an aminoglycoside or a fluoroquinolone.
Many extrinsic risk factors are inter-connected with intrinsic factors or are found in asso-
ciation, for which reason, the Study on the Efficacy of Nosocomial Infections Control 
(SENIC), a risk index, has been proposed for surgical wound infections. When compared 
to the traditional Altemeier system, this index predicts the risk of post-surgical infection 
two times better and the inclusion of other items does not seem to improve its predic-
tive capacity [26]. The National Surveillance System of Nosocomial Infections in the USA 
proposed the NNIS risk index, further completed with the item on the use of laparoscopic 
techniques (Tables 3 and 4).
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3. Management of antibacterial chemotherapeutic drugs
The choice of antibiotics is conditioned by:
• the characteristics of the isolated or suspected aetiological agent,
• patient characteristics, which may influence the efficiency and toxicity of the treatment 
(age, physiological status, comorbidities, infection site),
• pharmacodynamic and pharmacokinetic characteristics of the antibiotic (adsorption, tissue 
distribution, concentration in the infectious focus, metabolisation and elimination of the 
antibiotic).
In the case of the critical patients, the early administration of an effective antibiotic treatment 
is essential and determining, the time until the initiation of therapy being a strong predictor of 
mortality. A retrospective cohort study showed that the delay of effective treatment after the 
onset of recurrent or persistent hypotension was associated with an increased death risk; the 
survival rate in patients with treatment administered during the first hour was of 79.9%, with 
each hour of delay in antibiotic therapy leading to a 7.6% decrease in this rate [27].
Optimization of doses. The antibiotic requirement is calculated depending on the characteristics 
of the patient (age, weight, renal function), on the pathogenic microorganism, infection site 
Table 3. Risk indexes for post-surgical wound infections.
Table 4. Risk of post-surgical wound infection depending on the Altemeier classification.
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(endocarditis, pneumonia, meningitis, osteomyelitis) and the pharmacokinetic and pharma-
codynamic characteristics of the drug [28].
The loading dose is probably the most important and depends on the distribution volume 
of the drug and on the intended plasmatic concentration, regardless of the renal function. 
Antibiotics are classified according to multiple criteria, one being the criterion, which influ-
ences the dosage: the doses of hydrophilic antibiotics (beta-lactam) must be increased during 
the first stages of sepsis, together with the increase in the extravascular space. The doses of 
lipophilic antibiotics are influenced by other factors, such as obesity [7, 28].
Before establishing the rational antibiotics administration regimen, the antimicrobial activity 
in time must be understood, i.e., the pharmacodynamics of the drug in question (the relation-
ship between its serum concentration and its therapeutic effect). From a pharmacodynamic 
perspective, antimicrobial agents may be divided into:
• The bactericidal effect of beta-lactam antibiotics is independent of their concentration, as 
long as this exceeds the MIC and they do not possess a significant post-antibiotic effect 
(PAE) (The inhibition of bacterial growth continued for a variable period after the concen-
tration of antibiotic at the infection site has dropped under the MIC.) The strategy to obtain 
optimal results is to increase the exposure time of microbes to plasmatic concentrations of 
antibiotic exceeding the MIC, which is accomplished by frequent doses, by the administra-
tion at short time intervals or by continuous infusion.
• The bactericidal effect of vancomycin, carbapenems, macrolides, clindamycin, azoles, line-
zolid is independent of their concentration, if this is higher than the MIC, but it is time 
dependent. The PAE is intermediate (The serum antibiotic levels may drop under the MIC 
for a short while.) The antibiotics in this group produce optimal results when administered 
in lower but with more frequent doses.
• The bactericidal effect of aminoglycosides, fluoroquinolones and metronidazole is dose 
dependent and has a significant post-antibiotic effect (Bacterial growth is prevented even 
if tissue levels decrease under the MIC for longer periods of time.) This is why higher 
doses, but at larger intervals, may be administered, with 2–4 h between the doses after 
being admitted, during which time the plasmatic concentration of these antibiotics may be 
undetectable, which reduces their nephrotoxicity.
The time-dependent bactericidal effect is achieved by optimising the duration of bacterial 
exposure to antibiotics, while the dose-dependent bactericidal effect is maximal when the 
antibiotic concentration is maximal [7].
Polymyxins are concentration-dependent antibiotics; they are active on carbapenemase-pro-
ducing bacteria, and they are increasingly kept as last therapeutic option in infections with 
resistant pathogens, such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella 
pneumoniae. We must underline the fact that if sub-optimal doses of colistin are administered, 
the pathogen gains resistance.
First-line antibiotic treatment in severe acute infections.
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Severe acute infections are classified as community-acquired, healthcare-associated and hos-
pital-acquired infections. For the practical assessment of a case, Yehuda Carmeli proposed a 
score, which allows the stratification of risk factors for the infections with resistant or MDRO, 
depending on the previous contact of the patient with the health care sector, on the existence 
in his/her medical history of antibiotic treatments, as well as on associated factors (immune 
suppression, co-morbidities):
Risk assessment for infections with resistant or MDR pathogens:
a. Contact with the health care sector:
1. No contact—1
2. Contact without invasive procedures—2
3. Repeated contacts with invasive procedures—3
b. Previous antibiotic treatment:
1. No antibiotics—1
2. With antibiotics—2
c. Characteristics of the patient:
1. Young, without co-morbidities—1
2. Elderly, with co-morbidities—2
3. Immunocompromised patient (AIDS, neoplastic diseases)—3
According to this score, the value 1 corresponds to community-acquired infections, the value 
2 corresponds to HCAI and the value 3 to hospital-acquired infections. The Carmeli score 
may only be 1, 2 or 3, and it is given by the highest value obtained from the answers to the 
three categories of questions [29]. This classification allows a correlation between the type of 
infection, the most probable aetiology and the estimation of the antibiotic susceptibility of the 
microorganism in question.
The empirical or first-line treatment is especially important for the evolution of the infection; 
the delayed initiation of an effective antimicrobial treatment leads to increased morbidity 
and mortality, aggravated and generalised infections, as well as increased health care costs. 
If the initial treatment has not been effective, adding a new antibiotic or replacing the initial 
one with a broader spectrum antibiotic (escalation) will not increase the chance of favourable 
evolution. The adjustment of antibiotic treatment after the microbiological results become 
available might be tardy and ineffective, if the initial treatment has been inadequate, espe-
cially in the case of hospital-acquired infections (multivariate analysis have demonstrated 
that inadequate empirical treatment increased the risk of mortality). The association of antibi-
otics of different classes is useful in the initial treatment of infections with MDRO.
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Figure 2. Algorithm for initiation of antibiotic therapy.
In patients with severe infections, the recommendation is to administer the antibiotic treat-
ment during the first hour after the diagnosis, but not before collection of blood and other 
biological samples required for the identification of the aetiological agent and testing for its 
sensitivity to chemotherapeutics. Patients with meningitis will receive antibiotic treatment 
during the first 30 min after hospital admission, immediately after collection of blood and 
CSF [1, 10].
The empirical or first-line antibiotic treatment is initiated according to the most probable 
microbiological spectrum and consists of the administration of a broad-spectrum antibiotic 
(covering Gram-positive cocci, including MRSA and enterococci, as well as Gram-negative 
bacilli, including Acinetobacter spp., Pseudomonas aeruginosa and Enterobacter spp.) for a short 
period of time, i.e., for 2–3 days. Depending on the clinical evolution of the patient and on the 
results of microbiological tests, the initial treatment scheme may be modified by decreasing 
the number of antibiotics or reducing the spectrum (de-escalation). Narrowing the therapeutic 
regimen does not only refer to the shift from a broad-spectrum to a narrow-spectrum antibi-
otic, but also to adjusting (reducing) the doses and treatment duration [30].
Current Topics in Intensive Care Medicine32
The Principles of de-escalation are as follows:
• administration of an ultra-broad-spectrum antibiotic for a short period of time,
• identification of the aetiology within this covered period,
• replacement of the initial antibiotic with a narrow-spectrum antibiotic.
If, after 48–72 h of treatment with a broad-spectrum antibiotic, the status of the patient does 
not improve, the available microbiological data are attentively reanalysed and the possibility 
of MDRO infection, a non-bacterial or even a non-infectious aetiology, are considered. The 
evaluation must also include the possibility of a complication, such as the formation of an 
abscess, empyema, etc. [31].
Decreasing the risk of adverse reactions, the decreased selection pressure of resistant strains, 
as well as the reduction of costs represent the benefits of de-escalation and treatment cessation 
after a shorter time. Examples of benefits in the administration of antibiotics in short cures 
and/or reduction of the antibiotics spectrum include the decrease in the incidence of cases of 
diarrhoea with Clostridium difficile and of infections with resistant bacteria and Candida spp. 
(Figure 2).
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